Table 1.
Baseline patient characteristics
| Pre-ECMO team period (n = 70) | Post-ECMO team period (n = 46) | P value | |
|---|---|---|---|
| Age (years) | 61 (52–69) | 60 (52–64) | 0.672 |
| Male | 52 (74.3) | 34 (73.9) | 0.964 |
| Body mass index (kg/m2) | 23.1 (20.7–24.8) | 23.8 (20.6–25.8) | 0.163 |
| Comorbidity | |||
| Cardiovascular disease | 7 (10.0) | 5 (10.9) | >0.999 |
| Chronic renal failure | 6 (8.6) | 3 (6.5) | >0.999 |
| Asthma/COPD | 12 (17.1) | 2 (4.4) | 0.039 |
| Liver cirrhosis | 3 (4.3) | 3 (6.5) | 0.680 |
| Malignancy | 0.052 | ||
| Solid tumor | 18 (25.7)a | 6 (13.0)b | |
| Hematologic malignancy | 11 (15.7)c | 5 (10.9)d | |
| Immunocompromised state | 23 (32.9) | 17 (37.0) | 0.650 |
| Cardiac arrest before ECMO | 8 (11.4) | 10 (21.7) | 0.134 |
| Primary diagnosis | |||
| Bacterial pneumonia | 32 (45.7) | 12 (26.1) | 0.033 |
| Viral pneumonia | 2 (2.9) | 8 (17.4) | 0.014 |
| Interstitial lung disease | 15 (21.4) | 5 (10.9) | 0.141 |
| Trauma/burn | 2 (2.9) | 4 (8.7) | 0.212 |
| Asphyxia | 1 (1.4) | 1 (2.2) | >0.999 |
| Othere | 18 (25.7) | 16 (34.8) | 0.294 |
| Severity score on the first day in the ICU | |||
| APACHE II | 18 (15–25) | 25 (21–32) | <0.001 |
| SOFA | 6 (4–9) | 8 (6–14) | 0.003 |
| RESP score | 1 (−1 to 2) | 0 (−2 to 2) | 0.171 |
| PRESERVE score | 5 (4–7) | 6 (4–7) | 0.664 |
Values are given as the median (interquartile range) or n (%)
APACHE II acute physiology and chronic health evaluation II, COPD chronic obstructive pulmonary disease, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, PRESERVE predicting death for severe ARDS on VV-ECMO, RESP respiratory extracorporeal membrane oxygenation survival prediction, SOFA sequential organ failure assessment
aMeningioma (n = 1), malignant mesothelioma (n = 1), lung (n = 10), esophageal (n = 2), liver (n = 2), and colon cancer (n = 2)
bAcute myeloid leukemia (n = 3), acute lymphocytic leukemia (n = 1), chronic lymphocytic leukemia (n = 1), myelodysplastic syndrome (n = 4), and multiple myeloma (n = 2)
cGlioma (n = 1), lung cancer (n = 2), colon cancer (n = 2), and non-seminomatous germ cell tumor (n = 1)
dAcute myeloid leukemia (n = 1), multiple myeloma (n = 1), and lymphoma (n = 3)
eOther includes radiation therapy-induced pneumonitis, pulmonary tuberculosis, diffuse alveolar hemorrhage, pulmonary alveolar proteinosis, and airway occlusion by tumor mass or blood clot